

1 **Outcome of SARS-CoV-2 infection linked to MAIT cell activation and cytotoxicity:**  
2 **evidence for an IL-18 dependent mechanism**

3 **Authors:**

4 H. Flament<sup>1,\*</sup>, M. Rouland<sup>2,\*</sup>, L. Beaudoin<sup>2,\*</sup>, A. Toubal<sup>2,†</sup>, L. Bertrand<sup>2,†</sup>, S. Lebourgeois<sup>3,†</sup>, Z.  
5 Gouda<sup>2</sup>, C. Rousseau<sup>2</sup>, P. Soulard<sup>2</sup>, M. Hurtado-Nedelec<sup>1</sup>, S. Luce<sup>2</sup>, K. Bailly<sup>2</sup>, M. Andrieu<sup>2</sup>, C.  
6 Boitard<sup>2,4</sup>, A. Vallet-Pichard<sup>2,5</sup>, JF. Gautier<sup>6</sup>, N. Ajzenberg<sup>7</sup>, B. Terrier<sup>8</sup>, F. Pene<sup>2,9</sup>, J. Ghosn<sup>10</sup>, Y.  
7 Yazdanpanah<sup>10</sup>, B. Visseaux<sup>3</sup>, D. Descamps<sup>3</sup>, JF. Timsit<sup>11</sup>, R.C. Monteiro<sup>1</sup>, A. Lehuen<sup>2,\*</sup>

8 **Author affiliations:**

9 1. Immunological Dysfunction Unit, Assistance Publique-Hôpitaux de Paris, Bichat-Claude  
10 Bernard University Hospital, Paris, France ; University of Paris, Center for Research on  
11 Inflammation (CRI), Inserm U1149 & CNRS ERL8252, Inflammex Laboratory, Paris, France.

12 2. University of Paris, Institut Cochin, INSERM U1016, CNRS UMR 8104, Université de Paris,  
13 Paris, France.

14 3. Department of Virology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard  
15 University Hospital, Paris, France; Infections Antimicrobials Modelling Evolution (IAME) UMR  
16 1137, University of Paris, Paris, France.

17 4. Department of Diabetology, Assistance Publique-Hôpitaux de Paris, Cochin University  
18 Hospital, Paris, France.

19 5. Department of Hepatology, Assistance Publique-Hôpitaux de Paris, Cochin University  
20 Hospital, Paris, France.

21 6. Department of Diabetes and Endocrinology, Lariboisière Hospital, AP-HP, Paris, France.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

22 7. Department of Hematology, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard  
23 University Hospital, Paris, France; University of Paris, LVTS, INSERM 1148, Paris, France.

24 8. Medical Intensive Care Unit, Assistance Publique-Hôpitaux de Paris Cochin University  
25 Hospital, Paris, France.

26 9. Department of Internal Medicine, Assistance Publique-Hôpitaux de Paris, Cochin University  
27 Hospital, Paris, France.

28 10. Department of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris,  
29 Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials Modelling  
30 Evolution (IAME) UMR 1137, University of Paris, Paris, France.

31 11. Medical and Infectious Diseases Intensive Care Unit, Assistance Publique-Hôpitaux de  
32 Paris, Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials  
33 Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.

34

35 **Corresponding Author:** Agnès Lehuen, Institut Cochin, Université de Paris, CNRS UMR 8104  
36 and INSERM U1016, 123 Boulevard de Port-Royal, 75014 Paris, France. ORCID: 0000-0002-  
37 0450-3321; Phone: +331 76 53 55 90; E-mail: [agnes.lehuen@inserm.fr](mailto:agnes.lehuen@inserm.fr).

38 **•,†: These authors contributed equally to this work.**

39

40 **Keywords:** MAIT cells, COVID-19, SARS-CoV-2, inflammation, innate immune cells.

41

42

43 **Abstract:**

44 Immune system dysfunction is paramount in Coronavirus disease 2019 (COVID-19) severity  
45 and fatality rate. Mucosal-Associated Invariant T (MAIT) cells are innate-like T cells involved in  
46 mucosal immunity and protection against viral infections. Here, we studied the immune cell  
47 landscape, with emphasis on MAIT cells, in a cohort of 182 patients including patients at  
48 various stages of disease activity. A profound decrease of MAIT cell counts in blood of critically  
49 ill patients was observed. These cells showed a strongly activated and cytotoxic phenotype  
50 that positively correlated with circulating pro-inflammatory cytokines, notably IL-18. MAIT cell  
51 alterations markedly correlated with disease severity and patient mortality. SARS-CoV-2-  
52 infected macrophages activated MAIT cells in a cytokine-dependent manner involving an  
53 IFN $\alpha$ -dependent early phase and an IL-18-induced later phase. Therefore, altered MAIT cell  
54 phenotypes represent valuable biomarkers of disease severity and their therapeutic  
55 manipulation might prevent the inflammatory phase involved in COVID-19 aggravation.

56

57

58

59

60

61

62

63

64

65 **Introduction:**

66 The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the etiologic agent  
67 responsible for the recent outbreak of Coronavirus disease 2019 (Covid-19) that started in  
68 December 2019. Cellular targets of the SARS-CoV-2 are primarily upper- and lower respiratory  
69 tract cells as well as pulmonary cells<sup>1,2</sup>. The SARS-CoV-2 infection results in a wide range of  
70 clinical signs, from asymptomatic to life-threatening Acute Respiratory Distress Syndrome  
71 (ARDS), caused by a deleterious anti-viral immune response in the lung<sup>3-5</sup>. In serious cases,  
72 the overbalanced local immune response damages the airways and may lead to  
73 noncardiogenic pulmonary edema, hypoxia, and need for artificial ventilation and/or  
74 oxygenation<sup>6,7</sup>.

75 Innate-like T cells including Mucosal-associated invariant T (MAIT), invariant Natural Killer T  
76 (iNKT), and  $\gamma\delta$ T cells, are known to be key actors of pulmonary mucosal immunity, of mucosal  
77 tissue repair and are involved in the immune response to numerous respiratory pathogens<sup>8-</sup>  
78 <sup>13</sup>. Innate Lymphoid cells (ILCs) have also emerged as important mediators in tissue protection  
79 and repair during lung viral infection<sup>14,15</sup>. Among them, MAIT cells recognize bacterial  
80 metabolites derived from the riboflavin synthesis pathway and presented by the major  
81 histocompatibility complex (MHC) class-I-related protein (MR1)<sup>16,17</sup>. It has been established  
82 that MAIT cells are activated during viral infections, especially in blood and lungs<sup>18-20</sup>. MAIT  
83 cell activation by viruses is TCR-independent and cytokine-dependent<sup>18,20</sup>. During both acute  
84 and chronic viral infections, MAIT cell blood frequency is reduced while expression of HLA-DR,  
85 PD-1, CD38 and CD69 is upregulated<sup>18-20,22-24</sup>. Upon acute viral infection, they produce high  
86 levels of granzyme B (GzB)<sup>20</sup>.

87 In COVID-19 patients, alteration of peripheral lymphocyte and myeloid subsets is associated  
88 with clinical characteristics and treatment efficiency<sup>25-27</sup>. However, status of MAIT cells,  
89 remain unknown in COVID-19 patients. Here, we analyzed blood MAIT cells of COVID-19  
90 patients with different disease severity status from Infectious Disease Unit (IDU) (n=51) and  
91 Intensive Care Unit (ICU) (n=51). These patients were compared with uninfected controls  
92 (n=80) matched for age, sex and comorbidities. In COVID-19 patients, blood MAIT cells are  
93 altered in relation with disease severity and mortality. Macrophages infected *in vitro* with  
94 SARS-CoV-2 stimulate MAIT cells. Our study supports MAIT cells as a new indicator of COVID-  
95 19 gravity and suggest them as target to reduce COVID-19 morbidity.

96

## 97 **Results:**

### 98 **Adaptive and innate T cell frequency in the blood of COVID-19 patients.**

99 We first began our study of immune cells in SARS-CoV-2 infection by analyzing the frequency  
100 and phenotype of lymphocytes in blood samples from COVID-19 patients as well as (age-  
101 matched BMI-matched) non-infected donors (**Fig. 1a**). Fifty-one COVID-19 patients had been  
102 admitted in IDU (moderate cases) and 51 patients in ICU (severe cases) (with a death rate of  
103 41% in ICU). As controls, we included 80 healthy non-infected donors as well as donors with  
104 various pathologies (diabetes, obesity) to match those affecting hospitalized COVID-19  
105 patients (**Fig. 1a**). All characteristics and health data of recruited patients and controls are  
106 listed in **Table 1**. Whole blood was collected and stained for flow cytometry to analyze the  
107 frequencies of both innate and adaptive T lymphocytes following the gating strategy explained  
108 in **Supplementary Figure 1**. A majority of patients with COVID-19 presented a significant  
109 reduction of T cells in IDU, more pronounced in ICU patients (**Fig. 1b**), confirming earlier

110 reports<sup>28,29</sup>. Among CD3<sup>+</sup> T cells, there was a slight increase of blood  $\alpha\beta$  T cells frequency in  
111 ICU patients, mirrored by a decrease of  $\gamma\delta$ T cells (**Fig. 1c**). Both CD4<sup>+</sup> and CD8<sup>+</sup> T cell frequency  
112 among CD3<sup>+</sup> T cells were not significantly impacted by SARS-CoV-2 infection whereas T  
113 regulatory cell frequency was significantly reduced in both IDU and ICU patients compared to  
114 uninfected controls (**Fig. 1d**). We observed a collapse of V $\alpha$ 7.2<sup>+</sup> CD161<sup>+</sup> MAIT cell frequency  
115 among CD3<sup>+</sup> cells in COVID-19 patients, down to a tenth of those observed in uninfected  
116 controls (**Fig. 1e**). We confirmed that MAIT cell markers CD161 and V $\alpha$ 7.2 allowed similar MAIT  
117 cell identification as with MR1 tetramers loaded with the active ligand 5-(2-  
118 oxopropylideneamino)-6-D-ribitylamouracil (5-OP-RU) in all three groups of patients  
119 (**Supplementary Fig. 2**). Among MAIT cells, the CD8<sup>+</sup> subset was further reduced in COVID-19  
120 patients, but to a lesser extent in ICU compared to IDU (**Fig. 1f**). We therefore observed a  
121 dramatic decrease of blood MAIT cells in COVID-19 patients, with an alteration of MAIT cell  
122 subsets repartition.

123

#### 124 **MAIT cells are activated and cytotoxic in COVID-19 patients.**

125 As MAIT cell frequency is extremely reduced in blood of COVID-19 patients, we analyzed both  
126 their surface markers expression as well as their cytokine production. An activated phenotype  
127 with a dramatic increase of CD69 expression was observed in COVID-19 patients, with a  
128 median of 41% CD69<sup>+</sup> MAIT cells in IDU and 67% in ICU patients, with some reaching 100%  
129 (**Fig. 2a**). Blood MAIT cells also displayed a significant increase of the NK cell-associated  
130 activation CD56<sup>+</sup> marker compared to controls, that was highest in ICU patients (**Fig. 2a**).  
131 Accordingly, double positive CD56<sup>+</sup> CD69<sup>+</sup> MAIT cell frequency was increased in IDU patients  
132 and even more in ICU patients (**Fig. 2a**). The frequency of MAIT cells co-expressing CCR6, the

133 receptor for the CCL20 chemokine (a tissue-migrating marker) and survival CD127 marker was  
134 decreased, suggesting that the low circulating MAIT cell frequency might reflect their  
135 migration into inflamed infected tissues and/or activation-induced cell death (**Supplementary**  
136 **Fig. 3a**). MAIT cell activation in some patients might be associated with secondary infections  
137 and presence of bacteria in the blood (**Supplementary Fig. 3b**).

138 In contrast to MAIT cells, CD69<sup>+</sup> expression on CD8<sup>+</sup> T cell remained moderate (median of 10%)  
139 in both IDU and ICU although increased compared to uninfected controls (**Supplementary Fig.**  
140 **3c**). Frequency of CD56<sup>+</sup> CD8<sup>+</sup> T cells was similar in all three groups of patients. Consequently,  
141 the frequency of effector CD56<sup>+</sup> CD69<sup>+</sup> CD8<sup>+</sup> T cells was modestly increased in COVID-19  
142 patients compared to uninfected controls (**Supplementary Fig. 3c**).

143 We next investigated with unsupervised methods the phenotype of MAIT cells, on 9 flow-  
144 cytometry parameters. We first compared MAIT cells of COVID-19 patients to uninfected  
145 controls by Multidimensional scaling (MDS) plots, which revealed a severity progression from  
146 non-infected controls to IDU and ICU patients (**Fig. 2b**). We next performed graphical  
147 dimensional reduction by both t-distributed Stochastic Neighbor Embedding (t-SNE) and  
148 Uniform Manifold Approximation and Projection (UMAP) that also returned a progressive  
149 distribution of MAIT cells from controls to IDU and ICU patients (**Fig. 2c and Supplementary**  
150 **Fig. 4a,b**). Of note, both CD69 and CD56 markers were critical molecules in the differential  
151 distribution (**Fig. 2d and Supplementary Fig. 4c**).

152 MAIT cell function was then assessed after PMA/ionomycin stimulation by analyzing IFN $\gamma$  and  
153 GzB production in all three groups of patients and IL-2, IL-4, IL-10, IL-17 and TNF in IDU and  
154 ICU patients (**Fig. 2e,f and Supplementary Fig. 5a**). Production of IFN $\gamma$  was decreased in  
155 COVID-19 IDU patients compared to non-infected controls. However, IFN $\gamma$  and IL-2 increased

156 in ICU patients compared to IDU patients (**Fig. 2e** and **Supplementary Fig. 5a**). In contrast, GzB  
157 production progressively increased in stimulated MAIT cells in IDU and ICU patients as  
158 compared to controls. Elevated GzB production was also detected in unstimulated MAIT cells  
159 from infected patients (**Fig. 2f,g** and **Supplementary Fig. 5b**). Such enhanced cytokine and GzB  
160 production in ICU patients were not observed in conventional  $\alpha\beta$ T cells,  $\gamma\delta$ T cells and CD3<sup>-</sup>  
161 cells (including NK cells) (**Supplementary Fig. 5a,b**). Altogether, these results show that blood  
162 MAIT cells from COVID-19 patients display an activated/effector phenotype and cytotoxic  
163 function associated with disease severity.

164

#### 165 **Links between MAIT cell activation and other innate immune cell alterations**

166 Following MAIT cell analyses, we further investigated other innate-like immune cell frequency,  
167 phenotype and activation in the blood of SARS-CoV-2 infected patients. A significant NK cell,  
168 ILC2 and ILC3 frequency reduction in IDU and ICU patients was observed, which was more  
169 pronounced for NK cells and ILC2 in COVID-19 patients from ICU (**Fig. 3a**). CD69 expression  
170 was higher in all infected patients on NK cells, ILC3, and  $\gamma\delta$ T cells whereas it was reduced on  
171 ILC2 (**Fig. 3b**).

172 We sought to identify correlations between MAIT cells and other innate cells in COVID-19  
173 patients. A multiparametric matrix correlation plot showed strong positive correlations  
174 between the frequencies of activated MAIT cells (both CD56<sup>+</sup> and/or CD69<sup>+</sup> MAIT cells) with  
175 CD69<sup>+</sup> ILC3, NK and  $\gamma\delta$ T cells frequencies as well as CD69<sup>+</sup> CD56<sup>+</sup>  $\gamma\delta$ T cells (**Fig. 3c,d**). Several  
176 negative correlations were also observed between activation of these populations and their  
177 frequencies. CD69 expression on MAIT cells was negatively correlated with ILC3, ILC2 and NK  
178 cell frequencies (**Fig. 3c**). Moreover, cytokine production by MAIT cells was also negatively



179 correlated with ILC3 frequencies and to a lesser extent with ILC2 and NK cell frequencies.  
180 Taken together, these data suggest that inflammatory processes in SARS-CoV-2-infected  
181 patients involve concomitant activation of MAIT cells with other innate-immune cells  
182 associated with loss of these populations' frequencies in blood.

183

#### 184 **Fatal SARS-CoV-2 infection is linked with activation and function of MAIT cells.**

185 To investigate the impact of immune cell populations on disease outcome, blood samples  
186 were analyzed by comparing two groups, surviving versus fatal outcome of COVID-19 infected  
187 patients. CD69 expression significantly increased on MAIT, CD8 T,  $\gamma\delta$ T, and NK cells in fatal  
188 COVID-19 patients compared to surviving IDU and/or ICU patients (**Fig. 4a**). MAIT cells  
189 displayed the highest activation level in all patients, particularly those with fatal outcomes.  
190 We next examined immune cell function relative to disease outcome by measuring  
191 intracellular cytokines and GzB in stimulated and unstimulated immune cells (**Fig. 4b**,  
192 **Supplementary Fig. 6a,b** and data not shown). IFN $\gamma$ , TNF, and GzB in stimulated MAIT cells  
193 and GzB in unstimulated MAIT cells were significantly enhanced in deceased compared to  
194 surviving patients with SARS-CoV-2 infection (**Fig. 4b** and **Supplementary Fig. 6a,b**). IL-10  
195 production by stimulated  $\gamma\delta$ T cells in patients who succumbed was greater compared to  
196 surviving COVID-19 patients (**Fig. 4b** and **Supplementary Fig. 6a**). Thus, MAIT cell function was  
197 more associated to mortality than functions of other T cell populations. No modification of IL-  
198 2, IL-4, and IL-17 production in CD4<sup>+</sup>, CD8<sup>+</sup>, CD3<sup>-</sup>,  $\gamma\delta$ T, and MAIT cells was observed in fatal  
199 cases (**Fig. 4b** and **Supplementary Fig. 6a**). Moreover, statistical regression analyses identified  
200 four MAIT cell markers (IFN $\gamma$  production, stimulated GzB production, unstimulated GzB  
201 production, CD69) that defined predictive models for COVID-19 outcome, as tested on a

202 receiver-operating-characteristic (ROC) curve (**Fig. 4c**). In order to have a more global view of  
203 individual patients, we generated an heatmap based on multiple immune cell and blood  
204 parameters from single uninfected, infected and fatal COVID-19 patients. This analysis  
205 highlights activation signatures of non-surviving patients compared to surviving COVID-19  
206 patients and controls (**Fig. 4d**).

207

### 208 **Increased pro-inflammatory cytokine levels correlate with blood MAIT cell alterations.**

209 We next analyzed plasma levels of several cytokines by Cytometric Bead Array (CBA) and MSD  
210 Quickplex in both surviving IDU and ICU patients as well as non-surviving patients (**Fig. 5a,b**).  
211 IL-6, IL-8, IL-10, IL-15, and IL-18 levels were significantly increased in the plasma of non-  
212 surviving patients compared to surviving patients, confirming a state of widespread,  
213 pronounced inflammation in severe COVID-19 cases <sup>28</sup> (**Fig. 5a,b**). IFN $\alpha$ 2 levels were  
214 significantly decreased in ICU compared to IDU, although no significant difference between  
215 surviving ICU and deceased patients was detected (**Fig. 5b**). IL-1 $\beta$  levels were similar between  
216 all three groups (**Fig. 5b**). Multiparametric matrix correlation plot showed strong positive  
217 correlation of IL-6, IL-8, IL-10, IL-15, IL-18 levels with frequencies of CD69<sup>+</sup>, and CD69<sup>+</sup> CD56<sup>+</sup>  
218 MAIT cells in the blood of all COVID-19 patients (**Supplementary Fig. 7a,b**). IFN $\alpha$ 2 blood level  
219 correlated positively with the production of IFN $\gamma$ , TNF, and IL-2 by MAIT cells (**Supplementary**  
220 **Fig. 7a**).

221 Separated matrix correlation plot between surviving and non-surviving ICU patients showed  
222 different relationships between blood cytokines and GzB production by MAIT cells. In surviving  
223 patients, there was a strong negative correlation between blood IL-15 level and spontaneous  
224 GzB production by MAIT cells whereas in non-surviving patients there was a strong positive

225 correlation between blood IL-18 level and GzB MAIT production. The link between IL-18 and  
226 MAIT cell activation is further supported by high IL-18 $\alpha$  expression on all blood MAIT cells in  
227 control and COVID-19 infected compared to other immune populations (**Supplementary Fig.**  
228 **8a,b,c**). Interestingly, in non-surviving ICU patients, blood IL-18 level was negatively correlated  
229 with IFN $\alpha$ 2 blood levels (**Fig. 5c**). Accordingly, IL-18 blood level was increased in long-term  
230 infected ICU patients whereas IFN $\alpha$ 2 blood level was decreased in long-term in these patients  
231 (**Fig. 5d**). Of note, CD69<sup>+</sup> MAIT cell frequency increased as well with time and was highest one  
232 month after symptoms onset, when death rate was highest among ICU patients. Our data  
233 therefore reveal that pro-inflammatory cytokines and IL-10 levels are associated with MAIT  
234 cell activation and highlights a unique relationship between plasma IL-18 levels and circulating  
235 cytotoxic MAIT cells in fatal cases.

236

### 237 **MAIT cell phenotype and functions are associated with SARS-CoV-2 severity and clinical** 238 **parameters.**

239 As previously reported in our cohort, COVID-19 severity was associated with extended  
240 pulmonary damage as evaluated on chest computed tomography (CT) (score from 1:mild to  
241 5:critical) (**Fig. 6a**). PaO<sub>2</sub>/FiO<sub>2</sub> ratio was significantly reduced and C-reactive protein (CRP)  
242 levels were significantly increased in ICU patients. Both parameters were even more impacted  
243 in fatal cases (**Fig. 6b,c**).

244 A correlation matrix of MAIT cells activation, function and clinical parameters was established  
245 for all COVID-19 patients (**Fig. 6d**). It included age, body mass index (BMI), CRP, Simplified  
246 Acute Physiology Score II (SAPSII) (an estimator of patient mortality risk at ICU admission),  
247 PaO<sub>2</sub>/FiO<sub>2</sub> ratio, polymorphonuclear neutrophil (PMN), disease duration and pulmonary

248 lesions. Analysis of these clinical indicators in light of MAIT cells revealed that on vital  
249 parameters, PaO<sub>2</sub>/FiO<sub>2</sub> strongly negatively correlated with CD69<sup>+</sup> expression, IFN $\gamma$  and TNF  
250 production by MAIT cells, whereas SAPSII score positively correlated with CD69<sup>+</sup> MAIT cell  
251 frequency (**Fig. 6d,e**). Concerning inflammatory markers, CRP level correlated with MAIT cell  
252 activation phenotype and cytokine secretion (IL-2, IFN $\gamma$  and TNF) while PMN frequency  
253 positively correlated with CD69<sup>+</sup> MAIT cell frequency (**Fig. 6d,e**).

254 Principal Component Analysis (PCA) of all COVID-19 patients showed an unsupervised  
255 overview of all clinical data, cytokine levels, immune cell frequencies, activation, and functions  
256 for each COVID-19 patient (**Fig. 6f**). The PCA showed the segregation of deceased patients  
257 compared to surviving patients with CD69<sup>+</sup> MAIT cells being the most contributing variable  
258 (**Fig. 6g** and **Supplementary Fig. 9**). Of note, several parameters also contributed to the  
259 surviving/fatal cases discrimination vector such as blood IL-8, IL-15, IL-18, CRP, PMN, activated  
260 ILC3 and NK cells that we previously found to be correlated to MAIT cell activation (**Fig. 3c,d**,  
261 **Supplementary Fig. 9**, and **Fig. 6d,e**). Therefore, altered activation markers and cytokine  
262 production by blood MAIT cells correlate with clinical parameters and are associated with both  
263 severity and disease outcome.

264

#### 265 **SARS-CoV-2-infected macrophages activate MAIT cell *in vitro*.**

266 MAIT cells exert antiviral properties that are promoted especially by macrophages<sup>18,20</sup>. It has  
267 been established that macrophages and monocytes functions are impacted by SAR-CoV-2  
268 infection<sup>26,27</sup>. Using an *in vitro* co culture model we analyzed whether SARS-CoV-2-infected  
269 macrophages impacted MAIT cell phenotype. Blood monocytes isolated from healthy donors  
270 were cultured during 7 days and differentiated into mature macrophages (GM-M $\Phi$ ). GM-M $\Phi$

271 were then infected with SARS-CoV-2 at different multiplicity of infection (MOI) (0.3 or 3)  
272 during 2 hours and then cocultured with autologous PBMC or enriched MAIT cells for 24 to 96  
273 hours (**Fig. 7a**). Infected macrophages of 4 healthy donors (MOI=0.3 or 3) induced increased  
274 expression of CD69 on MAIT cells, when compared to uninfected macrophages (mock), in a  
275 dose dependent manner (**Fig. 7b**). Of note, although macrophage infection by SARS-CoV-2 was  
276 similar in all donors (**Fig. 7c**), level of MAIT cell activation by infected macrophages varied,  
277 suggesting intrinsic differences between individuals that modulate MAIT cell response upon  
278 infection. Other innate immune cells ( $\gamma\delta$ T and NK cells) were also activated by infected  
279 macrophages, however, to a lesser extent than MAIT cells. CD8, CD4 T cells or ILC3 co-culture  
280 (MOI=3) were almost unaffected (**Fig. 7d**). Analysis of several donors showed that MAIT cells  
281 were always activated, whereas it was not the case for other innate immune cells (**Fig. 7e**).

282 Since MAIT cells exert their antiviral activity in a cytokine dependent manner<sup>18,20</sup>, we next  
283 analyzed cytokine production by infected macrophages. Gene expression analysis showed  
284 that a short-term infection of macrophages by SARS-CoV-2 (24 hours) induced upregulation  
285 of their *Ifn $\alpha$* , *Ifn $\beta$* , *Il-1 $\beta$*  and *Il-6* expression compared to uninfected controls whereas *Il-10*, *Il-*  
286 *15* and *Il-18* expression was downregulated. While *Ifn $\alpha$* , *Ifn $\beta$* , *Il-1 $\beta$* , *Il-6*, *Il-10* and *Il-15*  
287 expression return to basal levels 4 days after infection, the expression of *Il-18* was upregulated  
288 (**Fig. 7f**). Finally, we observed that blockade of type I IFN, IL-12 and IL-18 completely inhibited  
289 MAIT cell activation of the donor 4 whereas it was only blocked by type I IFN inhibitor for the  
290 donor 5 (**Fig. 7g**). Altogether this data suggests that MAIT cell activation upon infection by  
291 SARS-CoV-2 is a two-step process. Early infection may induce MAIT cell activation through type  
292 I IFN pathways and later through the IL-18 pathway.

293

294 **Discussion:**

295 Our study reveals major MAIT cells alteration in numerous COVID-19 cases. MAIT cell  
296 frequency is strongly reduced in greater proportion than all other major T cell subsets and  
297 they are highly activated with secretion of critical pro-inflammatory cytokines, such as IFN $\gamma$ .  
298 MAIT cells possess a strong cytotoxic capability with an increased expression of GzB.  
299 Moreover, all these MAIT cell alterations scale with the severity of SARS-CoV-2 infection, from  
300 mild to fatal cases, and correlate with both plasmatic pro-inflammatory cytokine levels and  
301 other innate cell activation. *In vitro* experiments identified a SARS-CoV-2 macrophage cytokine  
302 shift and their ability to stimulate MAIT cells.

303 The frequency of blood MAIT cells was extremely reduced, down to a tenth compared to  
304 controls in severe cases of COVID-19<sup>30</sup>. Several hypotheses might explain this loss of blood  
305 MAIT cells. The tissue migration chemokine receptor CCR6 expression is decreased on blood  
306 MAIT cells during SARS-CoV-2 infection whereas its ligand, CCL20, is expressed by pro-  
307 inflammatory pulmonary macrophages<sup>31</sup>. Collapse of MAIT cell frequency in blood may be  
308 due to migration of CCR6<sup>+</sup> MAIT cells in the infected lung where they might participate to local  
309 immune response, as already demonstrated in other pulmonary infections mediated both by  
310 bacteria or viruses<sup>18,19</sup>. In addition, a recent study in a limited number of COVID-19 patients  
311 showed an increased pulmonary MAIT cell frequency in the broncho-alveolar lavage fluid<sup>30</sup>.  
312 Low blood MAIT cell frequency may also be due to their apoptosis. Expression of CD127,  
313 receptor for the pro-survival cytokine IL-7, is reduced on blood MAIT cells from infected  
314 patients. Moreover, MAIT cells are terminal effector T cell with high GzB expression,  
315 suggesting limited lifespan<sup>32</sup>.

316 MAIT cell frequency and activation alterations are characteristic of several deleterious  
317 inflammatory pathologies, especially metabolic pathologies such as T2D, liver disease or  
318 obesity<sup>10,33–36</sup>. MAIT cell frequency is reduced in blood from patients with those pathologies  
319 and they present an exhausted phenotype that may impair their antibacterial response<sup>34–36</sup>.  
320 This is of importance as metabolic pathologies are important factors increasing risk of  
321 developing severe COVID-19<sup>37–40</sup>. Thus, in our study, we matched our controls for  
322 comorbidities affecting COVID-19 patients, mainly obesity and diabetes. More than half of the  
323 ICU patients of our cohort developed secondary infections from mild tissue-specific infections  
324 to life-threatening septic shocks. Previous studies showed that high frequency of MAIT cells  
325 is associated with survival during septic shocks<sup>41</sup>. Similarly, patients co-infected by  
326 *Mycobacterium tuberculosis* and HIV are more vulnerable to tuberculosis because of a  
327 reduced MAIT cell frequency in blood<sup>23,42</sup>. COVID-19 patients with metabolic syndromes may  
328 therefore be extremely vulnerable to complications because of a diminished ability to fight  
329 both primary viral infection and secondary bacterial infections to a persistent depletion of  
330 blood MAIT cells.

331 Our data highlights strong positive correlations between blood NK, ILC3,  $\gamma\delta$ T and MAIT cell  
332 activation. In other lung pathologies such as asthma, CD69<sup>+</sup>-activated NK, ILCs, and MAIT cells  
333 are associated with airflow limitation<sup>43</sup>. We observed a significant correlation between MAIT  
334 cells activation and ILC2 frequency and it is already established that ILC2 are important drivers  
335 of allergen-induced airway hyperresponsiveness (AHR) after influenza A virus (IAV) infection  
336 <sup>14</sup>.

337 Blood cytokine analysis showed increased amounts of type I interferons and pro-inflammatory  
338 cytokines such as IL-6, IL-8 and the immunosuppressive IL-10 cytokines in COVID-19 patients

339 as previously reported<sup>28</sup>. Presence of elevated levels of IL-1 $\beta$ , IL-6, IL-8, and IL-10 are indicative  
340 of cytokine storms that are major potential complications in severe COVID-19 patients.  
341 Moreover, IL-15 and IL-18 levels were increased in COVID-19 patients in relation with disease  
342 severity and IL-18 strongly correlated with MAIT cell activation in patients with fatal outcome.  
343 In these patients, IFN $\alpha$ 2 level inversely correlated with increased IL-18. During the early  
344 phases of infection *in vitro*, macrophages produced important amounts of type I interferons  
345 which collapsed in later stages, around 4 days post-infection. This is in agreement with the  
346 ability of SARS-CoV-2 to suppress type I interferon production through numerous structural  
347 and non-structural viral proteins<sup>44</sup> and as highlighted in COVID-19 patient plasma analysis of  
348 ICU patients. However, long-term *in vitro* infected macrophages produce increased levels of  
349 IL-18 that can activate MAIT cells in COVID-19 corroborating the extremely high blood IL-18  
350 level correlating with MAIT cell activation in deceased patients. Both IL-15 and IL-18 are the  
351 most effective pro-inflammatory cytokines capable to activate MAIT cells in a TCR-  
352 independently manner during viral infection<sup>19</sup>. CD56<sup>+</sup> MAIT cells, which are increased in severe  
353 cases from our COVID-19 cohort, are known to have a higher capacity to respond to type I IFN  
354 and IL-18 cytokines that are key players in MR1-independent MAIT cell responses during viral  
355 infection<sup>45</sup>.

356 MAIT cells in inflammatory pathologies are double-edged swords. They can be protective by  
357 participating in and supporting pathogen clearance, immune activation and tissue  
358 repairment<sup>10,12,46</sup>. Patients infected with pandemic IAV harbor an inverse correlation between  
359 MAIT cell frequencies and disease severity, suggesting a protective role for MAIT cells<sup>18,20</sup>.  
360 Conversely, MAIT cells may fuel detrimental inflammation. Our data suggests a negative role  
361 for MAIT cells in severe COVID-19 infection in which their activation and GzB production are  
362 the highest. Against infection with Dengue virus (DV), there is a temporal and quantitative



363 association between the activation of MAIT cells and the onset of severe disease<sup>20</sup>. It is  
364 interesting to note that both the DV and the SARS-CoV-2 are able to infect macrophages,  
365 which then can activate MAIT cells<sup>47</sup>. Activation of MAIT cells by infected macrophages  
366 through IL-18 may switch MAIT cells toward a detrimental role in these infections.

367 In conclusion, human MAIT cells are activated, displaying a cytotoxic profile in the blood of  
368 SARS-CoV-2 infected patients, which is associated with other innate immune cell activation,  
369 and a pro-inflammatory environment. Together, these data extend the knowledge of the  
370 immune actors involved during SARS-CoV-2 infection. These findings reveal MAIT cells as a  
371 valuable biomarker of disease progression and a new target for interventional therapeutic  
372 approaches in severe SARS-CoV-2 infection.

373

374 **Materials and methods:**

375 **Clinical study design and ethical statement:**

376 One-hundred and two COVID-19 patients admitted in Bichat or Cochin hospitals, Paris, France,  
377 between March 23, 2020 and May 29, 2020 were included in this clinical study. For  
378 comparisons, blood from 80 uninfected controls of the Quid-Nash project (n=30),  
379 Etablissement Français du Sang (EFS) (n= 12), and volunteer donors (n=38) were mostly  
380 collected before pandemic onset (54/80). Clinical characteristics of the 182 patients are  
381 summarized in Fig. 1a and further detailed in Supplementary Table 1. No statistical methods  
382 were used to predetermine cohort size. The percentage of lung involvement was evaluated  
383 on chest CT with a score of 1 to 5 to represent mild to critical pulmonary lesions damages.  
384 Simplified Acute Physiology Score (SAPS II) was used to estimate the probability of survival  
385 after Intensive Care Unit (ICU) admission. The Ethics Committees approved clinical  
386 investigations. Informed consent was obtained from each enrolled patient. Patient's from  
387 Bichat Hospital (Paris, France) were included in the French COVID cohort (NCT04262921).  
388 Ethics approval for this cohort was given on February 5th, 2020 by the French Ethics  
389 Committee CPP-Ile de France- VI (ID CRB: 2020-A00256-33). This cohort is sponsored by  
390 Inserm and supported by the REACTing consortium and by the French Ministry of Health (PHRC  
391 n°20-0424). Samples from these patients were derived from samples collected in routine care.  
392 Patients from Cochin Hospital (Paris, France) were recruited in the setting of the local  
393 RADIPEM biological samples collection derived from samples collected in routine care.  
394 Biological collection and informed consent were approved by the Direction de la Recherche  
395 Clinique et Innovation (DRCI) and the French Ministry of Research (N°2019-3677).  
396 Investigations with control patients from QUID-NASH were approved by Comité de Protection

397 des Personnes de Sud Méditerranée (V) #18.021, N° of QUID project registration: 2018-  
398 A00311-54.

399

400 **Whole blood, PBMC and plasma isolation:**

401 Whole blood samples were collected in EDTA or heparin-coated tubes (Vacutaine, BD  
402 Biosciences) from healthy, non-infected, donors; and COVID-19 patients admitted to Cochin,  
403 Bichat, or Lariboisière Hospitals in Paris, France. Tubes were centrifugated at 1260g for 10  
404 minutes and plasma was collected and frozen at -80°C. PBMCs were isolated by Ficoll-Paque  
405 (Lymphosep, Biosera), frozen in 1mL of freezing medium constituted of 90% FCS and 10%  
406 DMSO and stored in liquid nitrogen.

407

408 **Cytokine measurements:**

409 IL-6, IL-8 and IL-10 were measured in plasma using Human Cytometric Bead Array (CBA)  
410 Inflammatory Cytokine Kit (BD Biosciences) according to manufacturer's instructions.  
411 Acquisitions were performed on a BD FACSLyric cytometer (BD Biosciences) and raw data  
412 analyzed with FCAP Array software V3.0 (BD Biosciences). For the IFN $\alpha$ 2 quantification, plasma  
413 samples were analyzed with the MSD Quickplex using the Ultra-sensitive assay S-PLEX Human  
414 IFN- $\alpha$ 2a (reference K151P3S-1) from Meso Scale Diagnostic MSD (Rockville, US) using 25  $\mu$ L of  
415 each sample. Each plasma sample was assayed twice with the average value taken as the final  
416 result. The unit for Human IFN- $\alpha$ 2a measured in the present study is fg.mL<sup>-1</sup>.

417 For IL-18, IL-15 and IL-1 $\beta$  quantification, the plasma samples were analyzed with the MSD  
418 Quickplex using the U-plex Biomarker group 1 (human) Assay (K-15067L-1) from Meso Scale

419 Diagnostic MSD, using 25  $\mu\text{L}$  of each (1/2 diluted) sample. Each plasma sample was assayed  
420 twice with the average value taken as the final result. The unit for Human IL18, IL-15 and IL-1 $\beta$   
421 measured in the present study is  $\text{pg}\cdot\text{mL}^{-1}$ .

422

### 423 **Flow cytometry:**

424 Surface and intracytoplasmic staining were performed on blood samples or PBMC with the  
425 following antibodies: CD3 (OKT3), CD19 (HIB19), CD4 (OKT4), CD8 (SK1), V $\alpha$ 7.2 (3C10), TCR-  
426  $\gamma\delta$  (B1), CD161 (HP-3G10), CCR6 (G034E3), CD56 (HCD56), CD69 (FN50), CD127 (R34.34),  
427 CD218a (H44), IFN $\gamma$  (4S.B3), TNF (Mab11), IL-2 (MQ1-17H12), IL-4 (8D4-8), IL-10 (JES3-  
428 19F1), IL-17 (BL168), granzyme B (GB11). Full list is described in **Supplementary Table 1**.

429 According to the amount of blood obtained from each patient, surface staining was always  
430 performed, and depending on number of cells, intracytoplasmic staining of cytokines and  
431 granzyme B were analyzed after stimulation with PMA-ionomycin-brefeldin A. Biotinylated  
432 human MR1 tetramers loaded with the active ligand 5-(2-oxopropylideneamino)-6-D-  
433 ribitylaminouracil (5-OP-RU) were used to confirm MAIT cells identification. MR1 tetramers  
434 were coupled to streptavidin-PE (National Institutes of Health tetramer core facility, USA).

435 For surface staining, staining of 200 $\mu\text{L}$  of blood sample was performed in PBS containing 1%  
436 BSA and 0.05% sodium azide. After surface staining, cells were fixated using BD FACS Lysing  
437 Solution (BD Biosciences, #349202) according to the manufacturer's instructions. Data  
438 acquisition was performed using a BD Biosciences LSR Fortessa. Flow cytometric analyses were  
439 performed with the FlowJo analysis software V10.6.2 (Tree Star).

440 For intracellular labelling, thawed PBMCs were treated with DNase (0.05  $\text{mg}\cdot\text{mL}^{-1}$ ) (#D4263,  
441 Sigma-Aldrich, USA) in RPMI (#61870-010, Gibco, USA) and incubated at 37°C, 5% CO $_2$  during

442 30 minutes. Depending on the number of PBMCs obtained from each patient, intracytoplasmic  
443 staining of cytokines and granzyme B were analyzed with stimulation with PMA (#P-8139,  
444 Sigma-Aldrich, USA) , ionomycin (#I-0634, Sigma-Aldrich, USA) and Brefeldin A (#B-7651,  
445 Sigma-Aldrich, USA) and/or only Brefeldin A. Stimulated cells were incubated during 6h at 37  
446 °C in RPMI medium supplemented with 10% FCS, 1% HEPES, 1% Penicillin/Streptomycin and  
447 stimulated with PMA (25 ng.mL<sup>-1</sup>) and ionomycin (1 µg.mL<sup>-1</sup>), in the presence of brefeldin A  
448 (10 µg.mL<sup>-1</sup>). After surface staining, cells were fixed and permeabilized with a  
449 Cytofix/Cytoperm kit (#554714, BD Biosciences, USA), then were washed using Perm/Wash  
450 buffer (BD Biosciences, #554723) and incubated at 4 °C in the dark for 30 min with antibodies  
451 against cytokines and GzB (listed above).

452

#### 453 ***In vitro* culture:**

454 For virus culture, the Vero E6 kidney epithelial cells line was acquired from the American Type  
455 Culture Collection (#CRL-1586, ATCC, USA) (LGC standards SARL, Illkirch, France). Vero E6 cells  
456 were cultured in DMEM (Gibco™) supplemented with 10% of heat-inactivated fetal bovine  
457 serum (FBS, Gibco™) (Thermo Fisher Scientific, Waltham, MA, 209 USA) and maintained at  
458 37°C in a humidified atmosphere containing 5% CO<sub>2</sub>. The viral strain of human SARS-CoV-2  
459 was obtained from a nasopharyngeal positive PCR sample. SARS-CoV-2 primo-culture stock  
460 used in this study was produced in Vero E6 cells and titrated by lysis plaque assay<sup>48</sup>. SARS-  
461 CoV-2 stock titer was 2.10<sup>7</sup> PFU.mL<sup>-1</sup>. Supernatant was aliquoted for storage at -80°C.

462 For viral titration, SARS-CoV-2 was titrated by lysis plaque assay as previously described<sup>49</sup>.

463 Vero E6 cells were plated onto 12-well plate at a density of 5.10<sup>4</sup> cells per well in DMEM with  
464 10% FBS. 24h later, cells were infected by 10 to 10 serial viral dilutions. After virus adsorption

465 for 1h at 37°C with plate rocking every 15 min, the viral inoculum was removed and Vero cells  
466 were washed with PBS free medium. After, 500µL of an agarose medium mix was added. After  
467 three days of incubation at 37°C with 5% CO<sub>2</sub>, supernatant was removed and cells were fixed  
468 with 1 mL of 6% formalin solution for 30 minutes. The formalin solution was removed and cells  
469 were colored with a 10% crystal violet solution for 15 minutes. All wells were then washed  
470 with distilled water and dried on bench-coat paper before analysis.

471 For macrophages in vitro infection by SARS-CoV-2, CD14<sup>+</sup> monocytes cells were isolated using  
472 StraightFrom® Whole Blood CD14 MicroBeads (#130-090-879, Miltenyi Biotec). 2.10<sup>5</sup>  
473 monocytes from one donor were added per culture well (96-flat-well plate). Monocytes were  
474 differentiated into macrophages by incubating CD14<sup>+</sup> monocytes cells for 7 days in X-VIVO15  
475 (#BE02-060F, Lonza, Switzerland) with 50 ng.mL<sup>-1</sup> of GM-CSF (#130-093-864, Miltenyi Biotec).

476 For infection, macrophages were washed two times in PBS and were treated with virus in non-  
477 supplemented RPMI at a MOI of 0.3 and 3 as determined based on the viral titer and the  
478 number of cells plated, for 90 to 120 min at 37 °C. The macrophages were washed three times  
479 with PBS before adding the lysis buffer into each well. The intracellular viral load Viral quantity  
480 was then determined by RT-qPCR (see below).

481

#### 482 **PBMC preparation and coculture with macrophages:**

483 PBMC were isolated from fresh blood samples using Lymphocyte Separation Media  
484 lymphosep LM-T1702/500 (Biosera). B cells, monocytes, and CD4<sup>+</sup> cells were depleted from  
485 PBMC of the same healthy donors using Dynabeads™ Untouched™ CD8<sup>+</sup> kit (#11348D,  
486 Invitrogen, USA) with an in-house antibody mix with the following biotinylated monoclonal  
487 anti-human antibodies CD4 (OKT4), CD14 (63D3) and CD19 (HIB19) from Biolegend. 2.10<sup>5</sup>

488 PBMCs or enriched MAIT cells per well were co-cultured with differentiated macrophages  
489 during either 24h or 96 hours. Blocking antibodies were used against IL-12p70 (MAB219, R&D  
490 systems) at  $5\mu\text{g.mL}^{-1}$  and IL-18 (D044-3, MBL) at  $5\mu\text{g.mL}^{-1}$ .  $1\mu\text{g.mL}^{-1}$  B18R (34-8185-81,  
491 eBioscience) was used to block Type I interferons<sup>50</sup>. After the coculture, macrophages were  
492 washed three times with PBS before adding the lysis buffer into each well. The intracellular  
493 viral quantity was then determined by RT-qPCR (see below).

494

#### 495 **RNA extraction and RT-qPCR:**

496 Total nucleic acids from cells and supernatant were extracted with the Total NA Isolation kit -  
497 Large Volume assay on a MagNA Pure LC 2.0 analyzer (Roche). Nucleic acids were eluted in  
498  $50\mu\text{L}$  of elution buffer and immediately tested by a quantitative PCR of the albumin gene for  
499 cellular DNA<sup>51</sup> and the RealStar™ SARS-CoV-2 RT-PCR Kit 1.0 (Altona Diagnostics GmbH) for  
500 SARS-CoV-2 detection. Viral RNA quantification was achieved using a standardized RNA  
501 transcript control acquired from the European Virus Archive Program.

502

#### 503 **Cytokine RNA quantification.**

504 cDNA was produced from total extracted nucleic acids as described above using Superscript  
505 III reverse transcriptase (#18080044; Invitrogen). Primers sequences used are described in  
506 **Supplementary Table 2**. Quantitative PCR analysis was performed with SYBR Green (#  
507 4887352001; Roche) and was analyzed with a LightCycler 480 (Roche). Relative expression  
508 was calculated by the  $2^{-\Delta\Delta\text{Ct}}$  method and was normalized to expression of the housekeeping  
509 gene encoding 18S and, when detailed, normalized on mock-infected macrophages.

510

511 **Statistics and Bioinformatics analysis:**

512 All bioinformatics analyses were performed using RStudio (1.2.5) running on R software  
513 version 4.0. We used the flowcytometry analysis R workflow from Nowicka et. al<sup>52</sup> to produce  
514 MDS (multidimensional scaling) plots of aggregated signal and normalized dimension  
515 reduction plot UMAP and t-SNE with 500 MAIT cells per patient from Bichat hospital flow  
516 cytometry data. Our pipeline combined this workflow with the flowWorkspace R library for  
517 FlowJo workspace reading and cell population selection. Multiparametric matrix correlation  
518 plots were produced with the adjusted rcorr function from Hmisc and RcmdrMisc packages to  
519 compute matrices of Spearman correlations along with the pairwise p-values corrected for  
520 multiple inferences using Holm's method and visualized with the Corrplot package.  
521 Correlation plots hierarchical clustering were produced with the hclust function included in  
522 the Corrplot library. Observations were filtered for missing values, and only complete  
523 observations were used. Principal component analysis (PCA) was processed with FactoMineR  
524 library and graphically produced with Factoextra package. Heatmaps were plotted using  
525 pheatmap library, with data centered to zero and scaled for each parameter. Clinical table  
526 values were computed with the atable R library. All R code written and used from our study is  
527 available at [github.com/MatthieuRouland/MAIT-COVID19](https://github.com/MatthieuRouland/MAIT-COVID19).

528 Statistical analyses were performed with GraphPad Prism software version 8.0 and R software  
529 version 4.0. All datasets were tested for normal distribution using Shapiro-Wilk normality test.  
530 Since all normality tests returned negative, all datasets were compared using nonparametric  
531 two-tailed Mann-Whitney. Correlation calculation between two parameters has been  
532 performed using the Spearman's correlation test corrected for multiple inferences using



533 Holm's method. Logistic regression and ROC (Receiver Operating Curve) were produced with  
534 XLSTATS 2020.4 and confirmed with a randomly-split cohort on R with the RORC package.  
535 Prognostic validity of the model was evaluated by analysis of the ROC curve and was measured  
536 using the area under the curve (AUC). Differences were considered significant at  $P < 0.05$   
537 (\* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ ).

538

539 **Acknowledgments:**

540 We thank all the patients and their physicians, nurses and technician staff who helped with  
541 the study. We thank the Department of Biological Hematology and the Department of  
542 Biochemistry of Bichat-Claude Bernard University Hospital for measuring white blood cells and  
543 C-reactive protein. We are grateful to Marc Diedisheim for biostatistics and bioinformatics  
544 discussion, Quentin Le Hingrat for help in virus experiments, Antoine Costa Monteiro for help  
545 in setting up the collaboration between virologists and immunologists, and the National  
546 Institutes of Health tetramer core facility for human MR1 tetramers. A.L. and R.C.M.  
547 laboratories are supported by ANR-11-IDEX-0005-02 Laboratory of Excellence INFLAMEX and  
548 Fondation pour la Recherche Médicale (EQU201903007779 to A.L. and EQU201903007816 to  
549 R.C.M.). R. C. M. received a Université de Paris COVID-19 grant. A. L. is also supported by ANR-  
550 17-CE14-0002-01, ANR-19-CE14-0020, Fondation Francophone pour la Recherche sur le  
551 Diabète. A. L., C. B., A. V.-P. and JF. G. are supported by RHU QUID-NASH (ANR-17-RHUS-009);  
552 M. R. and L.Ber. were supported by French Ministry of Research grants, A.T. and Z.G. were  
553 supported by RHU QUID-NASH; C. R. was supported by Fondation Francophone contre le  
554 Diabète, P. S. was supported by Juvenile Diabetes Research Foundation. Servier Medical Art  
555 for the free medical images (licensed under a Creative Commons Attribution 3.0 Unported  
556 License).

557

558 **Authors contribution:** H. F. collected most of the samples, clinical data and performed  
559 experiments; M. R. performed experiments and all bioinformatics analyses. L. Bea. performed  
560 experiments, analyzed data and managed experimental procedures. L. Ber analyzed data. A.  
561 T. and S. Le. performed in vitro experiments. S. Lu. collected samples. Z. G., C. R. and P. S.

562 performed flow cytometry experiments and analyses. M.H.N. performed CBA and K. B. and M.  
563 A. performed MSD Quickplex experiments. C. B., A. V.-P., JF. G., B. T., F. P., J. G., Y. Y. and JF.  
564 T. performed patient recruitment and analyzed clinical parameters. B.V. and D.D isolated and  
565 characterized SARS-CoV2. M. R., L. Bea., L. Ber., A. T., S. Le., H.F., R.C.M. and A. L. wrote the  
566 manuscript. H.F., L. Bea, R. C. M. and A. L. conceived the study. A. L. supervised the study. All  
567 authors edited and approved the manuscript.

568

569 **Conflict of interest statement:** The authors declare no conflict of interest.

570

571 **Data availability statement:** Data generated during this study will be available before  
572 publication in a repository. Access code will be given upon request.

573

574 **Code availability statement:** Code used during this study will be available before publication  
575 in a repository. Access code will be given upon request.

576

577

578 **References:**

- 579 1. Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion  
580 conformation. *Science* **367**, 1260–1263 (2020).
- 581 2. Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19:  
582 immunity, inflammation and intervention. *Nature Reviews Immunology* 1–12 (2020)  
583 doi:10.1038/s41577-020-0311-8.
- 584 3. Chen, N. *et al.* Epidemiological and clinical characteristics of 99 cases of 2019 novel  
585 coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **395**, 507–513  
586 (2020).
- 587 4. Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in  
588 Wuhan, China. *Lancet* **395**, 497–506 (2020).
- 589 5. Thompson, B. T., Chambers, R. C. & Liu, K. D. Acute Respiratory Distress Syndrome. *N.*  
590 *Engl. J. Med.* **377**, 562–572 (2017).
- 591 6. Matthay, M. A. *et al.* Acute respiratory distress syndrome. *Nature Reviews Disease*  
592 *Primers* **5**, 1–22 (2019).
- 593 7. Gorbalenya, A. E. *et al.* The species Severe acute respiratory syndrome-related  
594 coronavirus : classifying 2019-nCoV and naming it SARS-CoV-2. *Nature Microbiology* **5**,  
595 536–544 (2020).
- 596 8. Crosby, C. M. & Kronenberg, M. Tissue-specific functions of invariant natural killer T cells.  
597 *Nat Rev Immunol* **18**, 559–574 (2018).
- 598 9. McCarthy, N. E. & Eberl, M. Human  $\gamma\delta$  T-Cell Control of Mucosal Immunity and  
599 Inflammation. *Front. Immunol.* **9**, (2018).
- 600 10. Toubal, A., Nel, I., Lotersztajn, S. & Lehuen, A. Mucosal-associated invariant T cells and  
601 disease. *Nat. Rev. Immunol.* **19**, 643–657 (2019).

- 602 11. Trottein, F. & Paget, C. Natural Killer T Cells and Mucosal-Associated Invariant T Cells in  
603 Lung Infections. *Front Immunol* **9**, (2018).
- 604 12. Constantinides, M. G. *et al.* MAIT cells are imprinted by the microbiota in early life and  
605 promote tissue repair. *Science* **366**, (2019).
- 606 13. Leng, T. *et al.* TCR and Inflammatory Signals Tune Human MAIT Cells to Exert Specific  
607 Tissue Repair and Effector Functions. *Cell Rep* **28**, 3077-3091.e5 (2019).
- 608 14. Stehle, C., Hernández, D. C. & Romagnani, C. Innate lymphoid cells in lung infection and  
609 immunity. *Immunol. Rev.* **286**, 102–119 (2018).
- 610 15. Vivier, E. *et al.* Innate Lymphoid Cells: 10 Years On. *Cell* **174**, 1054–1066 (2018).
- 611 16. Treiner, E. *et al.* Selection of evolutionarily conserved mucosal-associated invariant T  
612 cells by MR1. *Nature* **422**, 164–169 (2003).
- 613 17. Corbett, A. J. *et al.* T-cell activation by transitory neo-antigens derived from distinct  
614 microbial pathways. *Nature* **509**, 361–365 (2014).
- 615 18. Loh, L. *et al.* Human mucosal-associated invariant T cells contribute to antiviral influenza  
616 immunity via IL-18-dependent activation. *Proc. Natl. Acad. Sci. U.S.A.* **113**, 10133–10138  
617 (2016).
- 618 19. Ussher, J. E., Willberg, C. B. & Klenerman, P. MAIT cells and viruses. *Immunology & Cell  
619 Biology* **96**, 630–641 (2018).
- 620 20. van Wilgenburg, B. *et al.* MAIT cells are activated during human viral infections. *Nat  
621 Commun* **7**, 11653 (2016).
- 622 21. Ussher, J. E. *et al.* CD161<sup>++</sup>CD8<sup>+</sup> T cells, including the MAIT cell subset, are specifically  
623 activated by IL-12+IL-18 in a TCR-independent manner. *Eur J Immunol* **44**, 195–203  
624 (2014).

- 625 22. Barathan, M. *et al.* Peripheral loss of CD8(+) CD161(++) TCRV $\alpha$ 7·2(+) mucosal-associated  
626 invariant T cells in chronic hepatitis C virus-infected patients. *Eur. J. Clin. Invest.* **46**, 170–  
627 180 (2016).
- 628 23. Leeansyah, E. *et al.* Activation, exhaustion, and persistent decline of the antimicrobial  
629 MR1-restricted MAIT-cell population in chronic HIV-1 infection. *Blood* **121**, 1124–1135  
630 (2013).
- 631 24. Leeansyah, E. *et al.* Arming of MAIT Cell Cytolytic Antimicrobial Activity Is Induced by IL-7  
632 and Defective in HIV-1 Infection. *PLoS Pathog.* **11**, e1005072 (2015).
- 633 25. Wang, F. *et al.* Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19  
634 Pneumonia. *J. Infect. Dis.* **221**, 1762–1769 (2020).
- 635 26. Silvin, A. *et al.* Elevated calprotectin and abnormal myeloid cell subsets discriminate  
636 severe from mild COVID-19. *Cell* (2020) doi:10.1016/j.cell.2020.08.002.
- 637 27. Schulte-Schrepping, J. *et al.* Severe COVID-19 is marked by a dysregulated myeloid cell  
638 compartment. *Cell* (2020) doi:10.1016/j.cell.2020.08.001.
- 639 28. Hadjadj, J. *et al.* Impaired type I interferon activity and inflammatory responses in severe  
640 COVID-19 patients. *Science* (2020) doi:10.1126/science.abc6027.
- 641 29. Zhang, J.-Y. *et al.* Single-cell landscape of immunological responses in patients with  
642 COVID-19. *Nat. Immunol.* (2020) doi:10.1038/s41590-020-0762-x.
- 643 30. Jouan, Y. *et al.* Functional alteration of innate T cells in critically ill Covid-19 patients.  
644 *medRxiv* 2020.05.03.20089300 (2020) doi:10.1101/2020.05.03.20089300.
- 645 31. Chua, R. L. *et al.* COVID-19 severity correlates with airway epithelium-immune cell  
646 interactions identified by single-cell analysis. *Nat. Biotechnol.* **38**, 970–979 (2020).
- 647 32. Dusseaux, M. *et al.* Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi  
648 IL-17-secreting T cells. *Blood* **117**, 1250–1259 (2011).

- 649 33. Hegde, P. *et al.* Mucosal-associated invariant T cells are a profibrogenic immune cell  
650 population in the liver. *Nat Commun* **9**, 2146 (2018).
- 651 34. Rouxel, O. *et al.* Cytotoxic and regulatory roles of mucosal-associated invariant T cells in  
652 type 1 diabetes. *Nat. Immunol.* **18**, 1321–1331 (2017).
- 653 35. Magalhaes, I. *et al.* Mucosal-associated invariant T cell alterations in obese and type 2  
654 diabetic patients. *J. Clin. Invest.* **125**, 1752–1762 (2015).
- 655 36. Toubal, A. *et al.* Mucosal-associated invariant T cells promote inflammation and  
656 intestinal dysbiosis leading to metabolic dysfunction during obesity. *Nat Commun* **11**,  
657 3755 (2020).
- 658 37. Zhou, F. *et al.* Clinical course and risk factors for mortality of adult inpatients with  
659 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054–1062 (2020).
- 660 38. Cariou, B. *et al.* Phenotypic characteristics and prognosis of inpatients with COVID-19  
661 and diabetes: the CORONADO study. *Diabetologia* **63**, 1500–1515 (2020).
- 662 39. Lisco, G. *et al.* Hypothesized mechanisms explaining poor prognosis in type 2 diabetes  
663 patients with COVID-19: a review. *Endocrine* (2020) doi:10.1007/s12020-020-02444-9.
- 664 40. Czernichow, S. *et al.* Obesity doubles mortality in patients hospitalized for SARS-CoV-2 in  
665 Paris hospitals, France: a cohort study on 5795 patients. *Obesity (Silver Spring)* (2020)  
666 doi:10.1002/oby.23014.
- 667 41. Grimaldi, D. *et al.* Specific MAIT cell behaviour among innate-like T lymphocytes in  
668 critically ill patients with severe infections. *Intensive Care Med* **40**, 192–201 (2014).
- 669 42. Cosgrove, C. *et al.* Early and nonreversible decrease of CD161<sup>++</sup> /MAIT cells in HIV  
670 infection. *Blood* **121**, 951–961 (2013).

- 671 43. Ishimori, A. *et al.* Circulating activated innate lymphoid cells and mucosal-associated  
672 invariant T cells are associated with airflow limitation in patients with asthma.  
673 *Allergology International* **66**, 302–309 (2017).
- 674 44. Lei, X. *et al.* Activation and evasion of type I interferon responses by SARS-CoV-2. *Nat*  
675 *Commun* **11**, 3810 (2020).
- 676 45. Dias, J., Leeansyah, E. & Sandberg, J. K. Multiple layers of heterogeneity and subset  
677 diversity in human MAIT cell responses to distinct microorganisms and to innate  
678 cytokines. *Proc Natl Acad Sci U S A* **114**, E5434–E5443 (2017).
- 679 46. Leng, T. *et al.* TCR and Inflammatory Signals Tune Human MAIT Cells to Exert Specific  
680 Tissue Repair and Effector Functions. *Cell Reports* **28**, 3077–3091.e5 (2019).
- 681 47. Blackley, S. *et al.* Primary human splenic macrophages, but not T or B cells, are the  
682 principal target cells for dengue virus infection in vitro. *J. Virol.* **81**, 13325–13334 (2007).
- 683 48. Hasnain, S. E. *et al.* Host-pathogen interactions during apoptosis. *J. Biosci.* **28**, 349–358  
684 (2003).
- 685 49. Gordon, D. E. *et al.* A SARS-CoV-2 protein interaction map reveals targets for drug  
686 repurposing. *Nature* **583**, 459–468 (2020).
- 687 50. Symons, J. A., Alcamí, A. & Smith, G. L. Vaccinia virus encodes a soluble type I interferon  
688 receptor of novel structure and broad species specificity. *Cell* **81**, 551–560 (1995).
- 689 51. Désiré, N. *et al.* Quantification of human immunodeficiency virus type 1 proviral load by  
690 a TaqMan real-time PCR assay. *J. Clin. Microbiol.* **39**, 1303–1310 (2001).
- 691 52. Nowicka, M. *et al.* CyTOF workflow: differential discovery in high-throughput high-  
692 dimensional cytometry datasets. *F1000Res* **6**, 748 (2017).
- 693
- 694



695 **Figure legends:**

696 **Figure 1. Immune cell frequencies and status in the blood of COVID-19 patients.** (a) Graphical  
697 representation of the COVID-19 cohort including a total of 182 patients from different  
698 hospitals and described as following: age, BMI, sex (F= Female, M= Male), diabetes, and  
699 fatality rates. Mean ( $\pm$  SD) values for each medical ward are represented. (b-c) Whole blood  
700 or Peripheral Blood Mononuclear Cells (PBMC) were collected from patients and analyzed  
701 through flow cytometry. Flow cytometry analysis of CD3<sup>+</sup> cells (b),  $\alpha\beta$ T cells and  $\gamma\delta$ T cells  
702 frequencies (c) from uninfected controls (n=80), COVID-19 patients hospitalized in an  
703 Infectious Disease Unit (IDU) (n=62) or hospitalized in an Intensive Care Unit (ICU) (n=66). (d)  
704 Flow cytometry analysis of CD4<sup>+</sup> cells, regulatory T cells (Treg), and CD8<sup>+</sup> T cell frequencies in  
705 the blood of patients as described in (b-c). (e-f) Representative dot plots of V $\alpha$ 7.2 and CD161  
706 staining to identify MAIT cells in blood of uninfected control and COVID-19 patients from IDU  
707 and ICU, and MAIT cell (e) and CD8<sup>+</sup> MAIT cell (f) frequencies in the blood of patients as  
708 described in (b-c). SSC, side scatter. Small horizontal lines indicate the median, each symbol  
709 represents one biological sample. \*P<0.05, \*\*P<0.01, \*\*\*P<0.001, and \*\*\*\*P<0.0001 (two-  
710 sided Mann-Whitney nonparametric test).

711

712 **Figure 2. Blood MAIT cells are activated and secrete pro-inflammatory cytokines in COVID-**  
713 **19 patients.** (a) Representative dot plots of CD69, CD56, and double-positive surface markers  
714 expression on blood MAIT cells from one uninfected control and two COVID-19 patients  
715 admitted in Infectious Disease Unit (IDU) and Intensive Care Unit (ICU) respectively. CD69<sup>+</sup>,  
716 CD56<sup>+</sup>, and CD56<sup>+</sup> CD69<sup>+</sup> MAIT cells frequencies in the blood of uninfected (n=80), and infected  
717 patients from IDU (n=62) and ICU (n=66). (b-c) Multi-Dimensional Scaling (MDS) plot (b) and

718 Uniform Manifold Approximation and Projection (UMAP) (c) analysis of MAIT cells for each  
719 uninfected (n=23) and infected patient from IDU (n=50) or ICU (n=66) from Bichat hospital  
720 analyzed with the same flow cytometer. (d) UMAP divided by groups and colored by the scaled  
721 expression of CD69 and CD56. (e-f) Representative dot plots and frequencies of IFN $\gamma$  (e),  
722 granzyme B (GzB) (f) in MAIT cells after stimulation from uninfected controls (n=25-27),  
723 COVID-19 patients hospitalized in an Infectious Disease Unit (IDU) (n=14-15) or hospitalized in  
724 an Intensive Care Unit (ICU) (n=15). (g) Representative dot plots and frequencies of GzB<sup>+</sup> MAIT  
725 cells without stimulation in uninfected controls (n=19), IDU (n=11), and ICU (n=14) COVID-19  
726 patients. SSC, side scatter. Small horizontal lines indicate the median, each symbol represents  
727 one biological sample. \*P<0.05, \*\*P<0.01, \*\*\*P<0.001, and \*\*\*\*P<0.0001 (two-sided Mann-  
728 Whitney nonparametric test).

729

730 **Figure 3: MAIT cells phenotype correlates with ILC and  $\gamma\delta$ T cells alteration in COVID-19**  
731 **patients. (a-b)** Frequencies of NK, ILC2, and ILC3 innate immune cells among CD3<sup>-</sup> CD19<sup>-</sup> cells  
732 (a) and CD69 activation surface marker on NK, ILC2, ILC3, and  $\gamma\delta$ T cells (b) in uninfected  
733 controls (n=80), COVID-19 patients hospitalized in an Infectious Disease Unit (IDU) (n=62) or  
734 hospitalized in an Intensive Care Unit (ICU) (n=66). (c) Multiparametric matrix correlation plot  
735 of MAIT,  $\gamma\delta$ T, ILCs, and NK cells frequencies, surface marker, and intracytoplasmic staining in  
736 COVID-19 patients. Spearman's correlation coefficients are visualized by square size and color  
737 intensity. Variables are ordered by hierarchical clustering. (d) Correlation between CD69<sup>+</sup>  
738 MAIT cells and CD69<sup>+</sup> NK, CD69<sup>+</sup> ILC3 or CD69<sup>+</sup>  $\gamma\delta$ T cells in COVID-19 patients (n=102). Small  
739 horizontal lines indicate the median, each symbol represents one biological sample. \*P<0.05,  
740 \*\*P<0.01, \*\*\*P<0.001, and \*\*\*\*P<0.0001 (two-sided Mann-Whitney nonparametric test and

741 Spearman nonparametric correlation test corrected for multiple inferences using Holm's  
742 method).

743

744 **Figure 4. MAIT cell activation and functions are altered in fatal compared to non-fatal COVID-**

745 **19. (a)** Frequency of CD69<sup>+</sup> cells among MAIT cells, conventional CD8<sup>+</sup> and CD4<sup>+</sup> T cells,  $\gamma\delta$ T

746 and NK cells in the blood of uninfected controls (n=80), surviving COVID-19 cases hospitalized

747 in an Infectious Disease Unit (IDU) (n=45) or hospitalized in an Intensive Care Unit (ICU) (n=30)

748 and fatal cases from both IDU and ICU (n=27). **(b)** Circular barplot representative negative

749 natural logarithm p-values of the frequency of immune cells (MAIT, CD8<sup>+</sup>, CD4<sup>+</sup>, CD3<sup>-</sup>,  $\gamma\delta$ T)

750 function including IL-2<sup>+</sup>, IL-4<sup>+</sup>, IL-10<sup>+</sup>, IL-17<sup>+</sup>, IFN $\gamma$ <sup>+</sup>, TNF<sup>+</sup>, and GzB<sup>+</sup> after stimulation or GzB<sup>+</sup>

751 without stimulation (Unstim) between fatal (n=5-6) and non-fatal (n=16-23) SARS-CoV-2

752 infected patients. The red-dotted circle represents a p-value of 0.05. **(c)** Receiver-operating-

753 characteristic (ROC) curves of the predictive MAIT cell markers defining the outcome of

754 COVID-19. **(d)** Heatmap showing the scaled expression of different innate-like immune cells

755 activation (MAIT, ILC3, NK,  $\gamma\delta$ T, CD8), C-reactive protein (CRP), and polynuclear neutrophil

756 (PPN) ordered by hierarchical clustering in uninfected controls (n=13), IDU (n=13), non-fatal

757 ICU (n=9) and fatal ICU (n=6). Each symbol **(a)** or columns **(d)** represents one patient. Up-

758 regulated parameters are shown in red, and down-regulated parameters are shown in navy

759 blue. \*P<0.05, \*\*P<0.01, \*\*\*P<0.001, and \*\*\*\*P<0.0001 (two-sided Mann-Whitney

760 nonparametric test).

761

762 **Figure 5. Pro-inflammatory cytokines are elevated in COVID-19 patients and match with**

763 **MAIT cell activation and cytokine secretion. (a)** Cytometric Bead Array (CBA) cytokine

764 quantification of IL-6, IL-8, and IL-10 in the blood of surviving COVID-19 cases hospitalized in  
765 Infectious Disease Unit (IDU) (n=19-22) or hospitalized in Intensive Care Unit (ICU) (n=19-28)  
766 and fatal cases (n=25). **(b)** MSD Quickplex cytokine quantification of IFN $\alpha$ 2, IL-1 $\beta$ , IL-15, and  
767 IL-18, in the blood of surviving COVID-19 cases hospitalized in IDU (n=14-22) or hospitalized in  
768 ICU (n=16-28) and fatal cases (n=20-25). Values under the limit of detection are not statistically  
769 computed and are not displayed. **(c)** Multiparametric matrix correlation plot of IL-6, IL-8, IL-  
770 15, IL-18, IFN $\alpha$  cytokines blood level; frequencies of CD69<sup>+</sup>, CD56<sup>+</sup>, CD69<sup>+</sup> CD56<sup>+</sup>, and GzB<sup>+</sup>  
771 MAIT cells; frequencies of IFN $\gamma$ <sup>+</sup>, IL-2<sup>+</sup>, TNF<sup>+</sup>, and GzB<sup>+</sup> stimulated MAIT cells; in non-fatal  
772 (upper right part, n=30) versus fatal COVID-19 patients in ICU (lower left part, n=21).  
773 Spearman's correlation coefficients are visualized by square size and color intensity. Variables  
774 are ordered by alphabetical order. **(d)** CD69<sup>+</sup> MAIT cells, IL-18, and IFN $\alpha$  blood levels according  
775 to symptoms duration (days) in COVID-19 patients, starting at the first clinical sign. Small  
776 horizontal lines indicate the median, each symbol represents one patient. \*P<0.05, \*\*P<0.01,  
777 \*\*\*P<0.001, and \*\*\*\*P<0.001 (two-sided Mann-Whitney nonparametric test and Spearman  
778 nonparametric correlation test corrected for multiple inferences using Holm's method).

779

780 **Figure 6: MAIT cell phenotype and blood cytokine levels are associated with SARS-CoV-2**  
781 **infection severity. (a-c)** Pulmonary damages score level (1: light - 5: critical) **(a)**, PaO<sub>2</sub>/FiO<sub>2</sub>  
782 ratio **(b)** and C-Reactive protein (CRP) **(c)** of surviving COVID-19 cases hospitalized in Infectious  
783 Disease Unit (IDU) (n=38, n=17, n=44) or hospitalized in Intensive Care Unit (ICU) (n=15, n=30,  
784 n=27) and fatal cases from IDU and ICU (n=20, n=27, n=23). **(d)** Multiparametric matrix  
785 correlation plot of the following clinical data: age, BMI, CRP, SAPS II score, PaO<sub>2</sub>/FiO<sub>2</sub>,  
786 Polymorphonuclear neutrophils (PMN), Disease duration, Pulmonary lesions score);

787 frequencies of CD69<sup>+</sup>, CD56<sup>+</sup>, CD69<sup>+</sup> CD56<sup>+</sup>, CCR6<sup>+</sup> CD127<sup>+</sup>, and GzB<sup>+</sup> MAIT cells; frequencies  
788 of IFN $\gamma$ <sup>+</sup>, IL-2<sup>+</sup>, TNF<sup>+</sup>, and GzB<sup>+</sup> stimulated MAIT cells; in the blood of all COVID-19 patients.  
789 Spearman's correlation coefficients are visualized by square size and color intensity. Variables  
790 are sorted by hierarchical clustering. **(e)** Correlation between PaO<sub>2</sub>/FiO<sub>2</sub> ratio (n=73), SAPS II  
791 score (n=46), CRP (n=94), and PMN (n=101) and the frequency of CD69<sup>+</sup> MAIT cells in blood  
792 (presented as a % value of total MAIT cells) from all COVID-19 patients. **(f-g)** Principal  
793 component analysis (PCA) of 50 variables (listed in Supplementary Fig. 9) including clinical data  
794 and frequencies of immune cell phenotype in IDU (n=46), ICU (n=30), and fatal cases from IDU  
795 (n=6) and ICU (n=21) infected patients. Each point represents a single patient. Mean value of  
796 each group is symbolized by a bigger symbol **(f)**. Arrows represent quantitatively the  
797 contributions of each variable in the PCA, the first 40 contributing parameters are displayed.  
798 Mean values of groups are represented by a symbol. Concentration ellipses with a confidence  
799 of 95% are shown **(g)**. Small horizontal lines indicate the median, each symbol represents one  
800 patient. \*P<0.05, \*\*P<0.01, \*\*\*P<0.001, and \*\*\*\*P<0.0001 (two-sided Mann-Whitney  
801 nonparametric test and Spearman nonparametric correlation test corrected for multiple  
802 inferences using Holm's method).

803

804 **Figure 7: Infected macrophages are altered and trigger MAIT cells *in vitro*.**

805 PBMCs of uninfected patients are challenged with infected macrophages with the SARS-CoV-  
806 2 virus. **(a)** Graphical flowchart of the *in-vitro* co-culture experiments. **(b)** Representative dot  
807 plot and frequency of CD69<sup>+</sup> MAIT cells in 4 healthy donors co-cultured with different SARS-  
808 CoV-2 Multiplicity of Infection (MOI) with mock, 0.3, and 3, with replicates (n=2-4). Each  
809 symbol represents the mean value of replicates. **(c)** Viral quantification of SARS-CoV-2 in co-


810 culture from four donors at 96h, by RT-qPCR. **(d-e)** Frequency of CD69<sup>+</sup> cells among MAIT cells,  
811 conventional CD8<sup>+</sup> and CD4<sup>+</sup> T cells,  $\gamma\delta$ T and NK cells in donor n°4 **(d)** and all donors **(e)** co-  
812 culture at 96h, with replicates (n=2-4). **(f)** Kinetic of *Ifn $\alpha$* , *Ifn $\beta$* , *Il-1 $\beta$* , *Il-6*, *Il-7*, *Il-10*, *Il-15*, and *Il-*  
813 *18* mRNA relative levels in infected macrophages from two healthy donors at 24h, 48h, and  
814 96h after infection. **(g)** Co-culture of infected macrophages (MOI 3) with PBMC (donor 4) or  
815 purified T cells (donor 5) with or without anti-IL-12, anti-IL-18, or recombinant soluble IFN $\alpha$   
816 receptor protein (B18R), with replicates (n=2-4). Each symbol represents a single co-culture  
817 well.

818

All rights reserved. No reuse allowed without permission.

| Group                               | Uninfected controls | IDU          | ICU          |
|-------------------------------------|---------------------|--------------|--------------|
| Number of patients                  | 80                  | 51           | 51           |
| Sex                                 |                     |              |              |
| Female                              | 40% (32)            | 33% (17)     | 18% (9)      |
| Male                                | 60% (48)            | 67% (34)     | 82% (42)     |
| Age                                 |                     |              |              |
| Median (MAD)                        | 58 ±20.9            | 61 ±14.8     | 59 ±14.8     |
| Mean (SD)                           | 54.9 ±17.5          | 61 ±16.4     | 57.6 ±13.3   |
| Range                               | 23-78.8             | 23-98        | 29-83        |
| BMI                                 |                     |              |              |
| Median (MAD)                        | 28 ±4.6             | 30 ±5.3      | 29 ±5.9      |
| Mean (SD)                           | 27.2 ±4.9           | 28.9 ±5.3    | 29.8 ±5.4    |
| Range                               | 18-38.3             | 17-38        | 21-43        |
| Hospital                            |                     |              |              |
| Bichat                              | 32% (26)            | 86% (44)     | 94% (48)     |
| Cochin                              | 26% (21)            | 14% (7)      | 5.9% (3)     |
| Beaujon-Lariboisière                | 26% (21)            | 0% (0)       | 0% (0)       |
| EFS                                 | 15% (12)            | 0% (0)       | 0% (0)       |
| Disease duration (days)             |                     |              |              |
| Median (MAD)                        | -                   | 10 ±5.9      | 18.5 ±13.3   |
| Mean (SD)                           | -                   | 13.5 ±11.9   | 24.5 ±16.7   |
| Range                               | -                   | 0-67         | 4-65         |
| Deaths                              | 0% (0)              | 12% (6)      | 41% (21)     |
| Treatments                          |                     |              |              |
| Tocilizumab                         | 0% (0)              | 2% (1)       | 12% (6)      |
| Anakinra                            | 0% (0)              | 12% (6)      | 33% (17)     |
| Lopinavir/Ritonavir                 | 0% (0)              | 33% (17)     | 57% (29)     |
| Anti-IFN $\beta$                    | 0% (0)              | 2% (1)       | 3.9% (2)     |
| Dexamethasone                       | 0% (0)              | 20% (10)     | 67% (34)     |
| Hydroxychloroquine                  | 0% (0)              | 5.9% (3)     | 18% (9)      |
| Pulmonary lesions                   |                     |              |              |
| Mild (score = 1)                    | 0% (0)              | 12% (6)      | 3.9% (2)     |
| Moderate (score = 2)                | 0% (0)              | 33% (17)     | 5.9% (3)     |
| Severe (score = 3)                  | 0% (0)              | 27% (14)     | 24% (12)     |
| Grievous (score = 4)                | 0% (0)              | 12% (6)      | 20% (10)     |
| Critical (score = 5)                | 0% (0)              | 0% (0)       | 3.9% (2)     |
| Missing                             | 100% (80)           | 16% (8)      | 43% (22)     |
| Pulmonary lesions score             |                     |              |              |
| Median (MAD)                        | -                   | 2 ±1.5       | 3 ±1.5       |
| Mean (SD)                           | -                   | 2.5 ±0.9     | 3.2 ±1       |
| Range                               | -                   | 1-4          | 1-5          |
| PaO <sub>2</sub> /FiO <sub>2</sub>  |                     |              |              |
| Median (MAD)                        | -                   | 306.5 ±160.1 | 158 ±108.2   |
| Mean (SD)                           | -                   | 345.3 ±176.9 | 194.2 ±144.8 |
| Range                               | -                   | 88-700       | 55-948       |
| SAPS II score                       |                     |              |              |
| Median (MAD)                        | -                   | 22 ±0        | 35 ±16.3     |
| Mean (SD)                           | -                   | 28.4 ±17.9   | 37.3 ±15.9   |
| Range                               | -                   | 16-60        | 9-78         |
| Polymorphonuclear neutrophils (PMN) |                     |              |              |
| Median (MAD)                        | 4.2 ±1.9            | 3.7 ±2.2     | 9.7 ±4.8     |
| Mean (SD)                           | 4.3 ±1.8            | 4.4 ±2.7     | 10.6 ±6      |
| Range                               | 2.1-8.5             | 1.1-15.7     | 2.9-30.2     |
| C-Reactive protein (CRP)            |                     |              |              |
| Median (MAD)                        | 1.5 ±1.2            | 66 ±60.8     | 95.2 ±93.4   |
| Mean (SD)                           | 2.6 ±2.1            | 72.2 ±59.3   | 125.7 ±97.6  |
| Range                               | 0.2-6.9             | 3-241        | 6-428        |
| Procalcitonin (PCT)                 |                     |              |              |
| Median (MAD)                        | -                   | 0.1 ±0.1     | 0.3 ±0.3     |
| Mean (SD)                           | -                   | 3.3 ±12.9    | 1.5 ±4.1     |
| Range                               | -                   | 0-55         | 0-18         |
| Type 2 Diabetes                     | 38% (30)            | 27% (14)     | 18% (9)      |
| HbA1c                               |                     |              |              |
| Median (MAD)                        | 7.4 ±0.9            | 7.7 ±1.9     | 6.6 ±0.7     |
| Mean (SD)                           | 7.6 ±1              | 8.1 ±2.4     | 6.8 ±1.2     |
| Range                               | 5.3-10.2            | 5.1-16.1     | 5.1-10.4     |
| Secondary Infection                 | 0% (0)              | 5.9% (3)     | 51% (26)     |
| Hospital acquired pneumonia         | 0% (0)              | 4% (2)       | 29.4% (15)   |
| Septic shock                        | 0% (0)              | 2% (1)       | 17.6% (9)    |

Table 1: COVID-19 and uninfected patients clinical characteristics.




**Figure 1**




All rights reserved. No reuse allowed without permission.


**a**




**b**




**c**




**d**




**e**



**f**




**g**




**Figure 2**








**Figure 5**



**Figure 6**



**Figure 7**